At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 101 enrolled
Drug / intervention
Vedolizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Phase 3b Study to Assess Mucosal Healing in Subjects With Moderately to Severely Active Crohn's Disease Treated With Vedolizumab IV
In Brief
A Phase 3 clinical trial evaluating Vedolizumab for Crohn's Disease. Completed, enrolled 101 participants across 79 sites in 8 countries.
Detailed Summary
The purpose of this study is to evaluate endoscopic remission at Week 26 as assessed by ileocolonoscopy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCrohn's Disease
CountriesBelgium, Canada, Czechia, France, Hungary, Italy, Poland, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartMar 2015
First PostedApr 2015
Primary CompletionJun 2017
Study CompletionFeb 2018
TodayJul 2026
First PostedApr 23, 2015
Enrollment StartMar 30, 2015
Primary CompletionJun 2, 2017
Study CompletionFeb 21, 2018
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 11.2 years ago
Interventions
Vedolizumabdrug
Vedolizumab intravenous injection